Experimental Alzheimer's drug fails to deliver in closely watched clinical trial

Share this article:

Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.

Lead investigator Reisa Sperling, M.D., told the New York Times that the experimental drug showed “no evidence at all of a clinical benefit of treatment on either of the primary measures, one cognitive and one functional,” compared to placebo. Three drug makers were jointly developing bapineuzumab: Pfizer, Elan and Johnson & Johnson

Scientists told the paper that bapineuzumab's failure, in addition to other recent drug failures, has raised doubts about whether beta- amyloid plaques — proteins in the brain that have been targeted by drug developers — are implicated in the progressive disease.

Earlier trials suggested that bapineuzumab is more successful in Alzheimer's patients a specific gene, called ApoE4, which raises the risk a person will get Alzheimer's disease and can make the disease worse. Trial results testing bapineuzumab in this population will conclude within the next couple months, according to the paper.

Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.